Clearside Biomedical Inc (NASDAQ:CLSD) Director Clay Thorp bought 8,000 shares of Clearside Biomedical stock in a transaction on Thursday, December 6th. The stock was purchased at an average price of $1.36 per share, with a total value of $10,880.00. Following the completion of the acquisition, the director now directly owns 8,000 shares of the company’s stock, valued at approximately $10,880. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Clearside Biomedical stock traded up $0.05 during trading hours on Thursday, reaching $1.41. The stock had a trading volume of 177,400 shares, compared to its average volume of 532,895. The company has a market capitalization of $43.55 million, a PE ratio of -0.61 and a beta of -4.34. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.59 and a current ratio of 4.59. Clearside Biomedical Inc has a 52 week low of $1.31 and a 52 week high of $15.33.
Clearside Biomedical (NASDAQ:CLSD) last announced its earnings results on Thursday, November 8th. The company reported ($0.75) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.12). On average, equities analysts predict that Clearside Biomedical Inc will post -2.57 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the company. Voya Investment Management LLC purchased a new stake in shares of Clearside Biomedical during the second quarter worth about $123,000. Bank of America Corp DE grew its stake in shares of Clearside Biomedical by 915.6% during the second quarter. Bank of America Corp DE now owns 16,574 shares of the company’s stock worth $177,000 after acquiring an additional 14,942 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Clearside Biomedical during the third quarter worth about $188,000. Engineers Gate Manager LP purchased a new stake in shares of Clearside Biomedical during the third quarter worth about $202,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Clearside Biomedical during the third quarter worth about $216,000. Institutional investors and hedge funds own 57.94% of the company’s stock.
A number of brokerages have commented on CLSD. Needham & Company LLC set a $4.00 target price on shares of Clearside Biomedical and gave the stock a “buy” rating in a report on Tuesday, November 6th. Zacks Investment Research upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Monday, August 13th. Laidlaw set a $5.00 target price on shares of Clearside Biomedical and gave the stock a “buy” rating in a report on Tuesday, November 6th. ValuEngine upgraded shares of Clearside Biomedical from a “hold” rating to a “buy” rating in a report on Tuesday, November 6th. Finally, Cowen downgraded shares of Clearside Biomedical from an “outperform” rating to a “market perform” rating in a report on Monday, November 5th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $12.71.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/12/06/clearside-biomedical-inc-clsd-director-purchases-10880-00-in-stock.html.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.
Featured Story: What is Cost of Capital?
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.